Skip to main content

Advertisement

SpringerLink
Log in

The change in tumor volume after induction chemotherapy with docetaxel plus cisplatin in 259 nasopharyngeal carcinoma patients

  • Head and Neck
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

Abstract

Purpose

To assess the tumor volume change after induction chemotherapy with docetaxel plus cisplatin (DP) in nasopharyngeal carcinoma (NPC).

Methods

A total of 259 non-metastatic NPC patients who received DP induction chemotherapy were retrospectively reviewed. Gross tumor volume of nasopharynx and lymph nodes (GTVnx and GTVnd) were contoured before and after chemotherapy. Univariate and multivariate analyses were performed to identify factors associated with tumor volume reduction.

Results

For GTVnx, the mean volume before and after chemotherapy were 43.2 cm3 vs 37.4 cm3 (p < 0.001) and the mean relative volume reduction was 12.7%. For GTVnd, the mean volume before and after chemotherapy were 24.6 cm3 vs 17.6 cm3 (p < 0.001) and the mean relative volume reduction was 13.9%. There was a positive linear correlation between the reduction of GTVnx and GTVnd (r = 0.351, p  < 0.001). For GTVnx volume reduction, pretreatment GTVnx volume (≤ 20 cm3 vs > 20 cm3, OR = 4.644, p = 0.001) and chemotherapy cycle (2 cycles vs 3 cycles, OR = 2.418, p = 0.009) were independently associated factors. For GTVnd volume reduction, pretreatment GTVnd volume (≤ 8 cm3 vs > 8 cm3, OR = 7.472, p < 0.001) and chemotherapy cycle (2 cycles vs 3 cycles, OR = 2.621, p = 0.007) were independently associated factors.

Conclusion

DP induction chemotherapy reduces tumor volumes moderately in NPC. Larger pre-treatment tumor volumes and three cycles of chemotherapy are associated with higher likelihood of tumor volume reduction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The raw data required to reproduce these findings cannot be shared at this time as the data also forms part of an ongoing study.

References

  1. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16(4):1310–1317. https://doi.org/10.1200/jco.1998.16.4.1310

    Article  CAS  PubMed  Google Scholar 

  2. Hong RL, Hsiao CF, Ting LL, Ko JY, Wang CW, Chang JTC, Lou PJ, Wang HM, Tsai MH, Lai SC, Liu TW (2018) Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Ann Oncol 29(9):1972–1979. https://doi.org/10.1093/annonc/mdy249

    Article  CAS  PubMed  Google Scholar 

  3. Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, Yu BK, Chiu SK, Kwan WH, Ho R, Chan I, Ahuja AT, Zee BC, Chan AT (2009) Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 27(2):242–249. https://doi.org/10.1200/jco.2008.18.1545

    Article  CAS  PubMed  Google Scholar 

  4. Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J (2016) Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 17(11):1509–1520. https://doi.org/10.1016/s1470-2045(16)30410-7

    Article  CAS  PubMed  Google Scholar 

  5. Zheng L, Liao W, Xu P, Li B, Wen H, Zhang S (2018) Tumor volume reduction after gemcitabine plus cisplatin induction chemotherapy in locally advanced nasopharyngeal cancer: comparison with paclitaxel and cisplatin regimens. Med Sci Monit 24:8001–8008. https://doi.org/10.12659/msm.909736

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Lee AW, Lau KY, Hung WM, Ng WT, Lee MC, Choi CW, Chan CC, Tung R, Cheng PT, Yau TK (2008) Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. Radiotherapy Oncol 87(2):204–210. https://doi.org/10.1016/j.radonc.2008.02.003

    Article  CAS  Google Scholar 

  7. Wang L, Wu Z, Xie D, Zeng R, Cheng W, Hu J, Huang S, Zhou S, Zhong R, Su Y (2019) Reduction of target volume and the corresponding dose for the tumor regression field after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Cancer Res Treatment 51(2):685–695. https://doi.org/10.4143/crt.2018.250

    Article  CAS  Google Scholar 

  8. Saraste D, Jaras J, Martling A (2020) Population-based analysis of outcomes with early-age colorectal cancer. British J Surg. https://doi.org/10.1002/bjs.11333

    Article  Google Scholar 

  9. Zhou Q, He Y, Zhao Y, Wang Y, Kuang W, Shen L (2017) A study of 358 cases of locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiation therapy: improving the seventh edition of the american joint committee on cancer T-staging system. BioMed Res Int https://doi.org/10.1155/2017/1419676

  10. Li C, Pei Q, Zhu H, Tan F, Zhou Z, Zhou Y, Li Y, Pei H (2018) Survival nomograms for stage III colorectal cancer. Medicine 97(49):e13239. https://doi.org/10.1097/md.0000000000013239

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sze WM, Lee AW, Yau TK, Yeung RM, Lau KY, Leung SK, Hung AW, Lee MC, Chappell R, Chan K (2004) Primary tumor volume of nasopharyngeal carcinoma: prognostic significance for local control. Int J Radiat Oncol Biol Phys 59(1):21–27. https://doi.org/10.1016/j.ijrobp.2003.10.027

    Article  PubMed  Google Scholar 

  12. Fangzheng W, Chuner J, Zhimin Y, Quanquan S, Tongxin L, Min X, Peng W, Bin L, Sakamoto M, Yuezhen W, Fengqin Y, Zhenfu F, Yangming J (2017) Association of the neoadjuvant chemotherapy cycle with survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a propensity-matched analysis. Oncotarget 8(55):94117–94128. https://doi.org/10.18632/oncotarget.21587

    Article  PubMed  PubMed Central  Google Scholar 

  13. Wei J, Feng H, Xiao W, Wang Q, Qiu B, Liu S, Deng M, Lu L, Chang H, Gao Y (2018) Cycle number of neoadjuvant chemotherapy might influence survival of patients with T1–4N2–3M0 nasopharyngeal carcinoma. Chinese J Cancer Res Chung-kuo yen cheng yen chiu 30 (1):51–60. https://doi.org/10.21147/j.issn.1000-9604.2018.01.06

  14. Liu SL, Sun XS, Li XY, Tang LQ, Chen QY, Lin HX, Liang YJ, Yan JJ, Lin C, Guo SS, Liu LT, Li Y, Xie HJ, Tang QN, Liang H, Guo L, Mai HQ (2019) The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study. Cancer Commun (London, England) 39(1):14. https://doi.org/10.1186/s40880-019-0357-9

    Article  Google Scholar 

  15. Li X, Dai D, Chen B, Tang H, Xie X, Wei W (2018) The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis. J Cancer 9(5):861–871. https://doi.org/10.7150/jca.23367

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Cuello-Lopez J, Fidalgo-Zapata A, Lopez-Agudelo L, Vasquez-Trespalacios E (2018) Platelet-to-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer. PLoS ONE 13(11):e0207224. https://doi.org/10.1371/journal.pone.0207224

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Peng Y, Chen R, Qu F, Ye Y, Fu Y, Tang Z, Wang Y, Zong B, Yu H, Luo F, Liu S (2020) Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients. Cancer Biol Ther 21(2):189–196. https://doi.org/10.1080/15384047.2019.1680057

    Article  CAS  PubMed  Google Scholar 

  18. Habibzadeh F, Habibzadeh P, Yadollahie M (2016) On determining the most appropriate test cut-off value: the case of tests with continuous results. Biochemia medica 26(3):297–307. https://doi.org/10.11613/bm.2016.034

    Article  PubMed  PubMed Central  Google Scholar 

  19. Yuan C, Xu XH, Luo SW, Wang L, Sun M, Ni LH, Xu L, Wang XL, Zeng G (2018) Which neoadjuvant chemotherapy regimen should be recommended for patients with advanced nasopharyngeal carcinoma?: A network meta-analysis. Medicine 97(34):e11978. https://doi.org/10.1097/md.0000000000011978

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Peng H, Chen L, Zhang Y, Li WF, Mao YP, Liu X, Zhang F, Guo R, Liu LZ, Tian L, Lin AH, Sun Y, Ma J (2016) The tumour response to induction chemotherapy has prognostic value for long-term survival outcomes after intensity-modulated radiation therapy in nasopharyngeal carcinoma. Sci Rep 6:24835. https://doi.org/10.1038/srep24835

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Oubel E, Bonnard E, Sueoka-Aragane N, Kobayashi N, Charbonnier C, Yamamichi J, Mizobe H, Kimura S (2015) Volume-based response evaluation with consensual lesion selection: a pilot study by using cloud solutions and comparison to RECIST 1.1. Acad Radiol 22 (2):217–225. https://doi.org/10.1016/j.acra.2014.09.008

  22. Aghighi M, Boe J, Rosenberg J, Von Eyben R, Gawande RS, Petit P, Sethi TK, Sharib J, Marina NM, DuBois SG, Daldrup-Link HE (2016) Three-dimensional radiologic assessment of chemotherapy response in ewing sarcoma can be used to predict clinical outcome. Radiology 280(3):905–915. https://doi.org/10.1148/radiol.2016151301

    Article  PubMed  Google Scholar 

  23. Wang HM, Wang CH, Chen JS, Chang HK, Kiu MC, Liaw CC, Ng KT, Lai GM (1995) Cisplatin and 5-fluorouracil as neoadjuvant chemotherapy: predicting response in head and neck squamous cell cancer. J Formosan Med Assoc Taiwan yi zhi 94 (3):87–94

  24. Nguyen-Kim TD, Frauenfelder T, Strobel K, Veit-Haibach P, Huellner MW (2015) Assessment of bronchial and pulmonary blood supply in non-small cell lung cancer subtypes using computed tomography perfusion. Invest Radiol 50(3):179–186. https://doi.org/10.1097/rli.0000000000000124

    Article  PubMed  Google Scholar 

  25. Kim ES (2016) Chemotherapy resistance in lung cancer. Adv Exp Med Biol 893:189–209. https://doi.org/10.1007/978-3-319-24223-1_10

    Article  PubMed  Google Scholar 

  26. Ji X, Yang Q, Qin H, Zhou J, Liu W (2019) Tumor blood supply may predict neoadjuvant chemotherapy response and survival in patients with gastric cancer. J Int Med Res 47(6):2524–2532. https://doi.org/10.1177/0300060519845491

    Article  PubMed  PubMed Central  Google Scholar 

  27. Fleming CA, McCarthy K, Ryan C, McCarthy A, O’Reilly S, O’Mahony D, Browne TJ, Redmond P, Corrigan MA (2018) Evaluation of discordance in primary tumor and lymph node response after neoadjuvant therapy in breast cancer. Clin Breast Cancer 18(2):e255–e261. https://doi.org/10.1016/j.clbc.2017.11.016

    Article  PubMed  Google Scholar 

  28. Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B (2017) The different mechanisms of cancer drug resistance: a brief review. Adv Pharmac Bull 7(3):339–348. https://doi.org/10.15171/apb.2017.041

    Article  CAS  Google Scholar 

  29. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. https://doi.org/10.1056/NEJMoa043331

    Article  CAS  PubMed  Google Scholar 

  30. Ge Y, He Z, Xiang Y, Wang D, Yang Y, Qiu J, Zhou Y (2019) The identification of key genes in nasopharyngeal carcinoma by bioinformatics analysis of high-throughput data. Mol Biol Rep 46(3):2829–2840. https://doi.org/10.1007/s11033-019-04729-3

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Letpub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

Funding

This work was supported by National Natural Science Foundation of China (Grant No. 81974466).

Author information

Authors and Affiliations

  1. Department of Oncology, Xiangya Hospital, Central South University, No. 87, Xiangya Road, Changsha, 410008, Hunan Province, China

    Shan Li & Liangfang Shen

Authors
  1. Shan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liangfang Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Liangfang Shen conceived and designed the study; Shan Li collected the data and performed the analysis; Liangfang Shen and Shan Li wrote the paper.

Corresponding author

Correspondence to Liangfang Shen.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

This study was approved by the Ethics Committee of the Xiangya Hospital of Central South University prior to commencement [IRB number: 201912531] and was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.

Consent to participate

Written informed consent was obtained from each participant.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (TIF 25131 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, S., Shen, L. The change in tumor volume after induction chemotherapy with docetaxel plus cisplatin in 259 nasopharyngeal carcinoma patients. Eur Arch Otorhinolaryngol 278, 3027–3035 (2021). https://doi.org/10.1007/s00405-020-06477-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-020-06477-8

Keywords

Search

Navigation